Comparison · NCT02954991-e17ae9d5
CIT Experienced: Sitravatinib and Nivolumab vs CIT Naïve: Sitravatinib and Nivolumab: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CIT Experienced: Sitravatinib and Nivolumab vs CIT Naïve: Sitravatinib and Nivolumab: Number of Participants With Treatment-emergent Adverse Events (TEAEs). Trial comparisons, record NCT02954991-e17ae9d5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02954991-e17ae9d5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.992 | 0.956 | 0.999 | wilson | |
| Risk in group 2 | 1 | 0.893 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00806 | -0.0443 | 0.0993 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.992 | 0.976 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on CIT Experienced: Sitravatinib and Nivolumab than on CIT Naïve: Sitravatinib and Nivolumab | 124 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CIT Experienced: Sitravatinib and Nivolumab | Participants who had previously received checkpoint inhibitor therapy (CIT) received sitravatinib 120 mg oral capsules once daily (QD) in combination with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks intravenously. | 123 | 124 | OG000 |
| Group 2 | CIT Naïve: Sitravatinib and Nivolumab | Participants who had not previously received CIT received sitravatinib 120 mg oral capsules QD in combination with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks intravenously. | 32 | 32 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Description
TEAEs were defined as any event that first occur or increase in severity on or after the first dose of study treatment and not more than 28 days after the last dose of study treatment and prior to the initiation of subsequent systemic anti- cancer therapy.~Any clinically significant changes in laboratory tests were recorded as TEAEs.
- Time frame
- Day 1 up to 28 days after the last dose (median time on treatment was: CIT experienced 3.7 months; CIT naïve 4.8 months)
- Population
The Safety Population was defined as all participants who received at least 1 dose of any study treatment (sitravatinib, glesatinib, or nivolumab). Per statistical analysis plan, only AEs for sitravatinib + nivolumab will be summarized. TEAE tables for glesatinib + nivolumab were not produced and therefore will not be reported here.
Source ClinicalTrials.gov
Trial
- Title
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
- NCT number
- NCT02954991
- Phases
- PHASE2
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Glesatinib, Sitravatinib, Mocetinostat, Nivolumab
- Lead sponsor
- Mirati Therapeutics Inc.
- Results first posted
- 2024-04-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02954991?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02954991-e17ae9d5